UBS Group
IOVA icon

UBS Group’s Iovance Biotherapeutics IOVA Stock Holding History

UBS Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,000
Closed -$415K – 8166
2019
Q4 		$415K Buy
+15,000
New +$341K ﹤0.01% 5004

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

UBS Group's IOVA Position: Q1 2026 in Review

UBS Group increased its Iovance Biotherapeutics (IOVA) stake by 151% in Q1 2026, buying an estimated $3.69M and bringing the position to 1,916,704 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

UBS Group first reported a position in IOVA in Q1 2015 and has held it in 45 quarters since. The position peaked at $20M in Q4 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • UBS Group held 1,916,704 shares of Iovance Biotherapeutics worth $6.73M as of Q1 2026.
  • UBS Group bought 1,152,550 Iovance Biotherapeutics shares in Q1 2026, an estimated $3.69M.
  • Iovance Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3763 holding.
  • UBS Group first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 45 quarters since.
  • UBS Group's Iovance Biotherapeutics position peaked at $20M in Q4 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.